Therapy-related side effects and severe antimicrobial resistance still remain an obstacle to Helicobacter pylori eradication. This meta-analysis aimed to investigate the efficacy of Lactobacillus-supplemented triple therapy on H. pylori eradication rates and therapy-related side effects in children. Five studies involving 484 pediatric patients were included in our analysis. The pooled relative risk (RR) for eradication rates in the Lactobacillus group versus the control group was 1.19 [95% confidence interval (CI) 1.07–1.33]. In subgroup analyses based on dose and duration of Lactobacillus supplementation, the pooled RRs for eradication rates were 1.36 (95% CI 1.15–1.60) in the high-dose group, 1.08 (95% CI 0.86–1.35) in the low-dose group, 1.24 (95% CI 1.06–1.46) in the long-term group, and 1.17 (95% CI 0.96–1.44) in the short-term group. With respect to side effects, Lactobacillus supplementation significantly reduced the incidence of diarrhea (RR = 0.30, 95% CI 0.10–0.85).
Conclusions: Lactobacillus, as an adjunct to triple therapy, can increase H. pylori eradication rates as well as reduce the incidence of therapy-related diarrhea in children. And a higher dose and a longer duration of supplementation may conduce to the positive impact of Lactobacillus on H. pylori eradication.
What is Known:
• Probiotics-supplemented triple therapy may be beneficial in improving H. pylori eradication rates and reducing therapy-related side effects in children. However, not all probiotics are beneficial to H. pylori eradication and the pooled outcomes based on different probiotics may be erroneously extrapolated to other ineffective strains.
What is New:
• Lactobacillus, as an adjunct to triple therapy, can increase H. pylori eradication rates as well as reduce the incidence of therapy-related diarrhea in children.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
H. pylori stool antigen test
Nonsteroidal anti-inflammatory drug
Randomized controlled trial
Rapid urease test
Proton pump inhibitor
Urea breath test
Jones NL, Koletzko S, Goodman K, Bontems P, Cadranel S, Casswall T, Czinn S, Gold BD, Guarner J, Elitsur Y, Homan M, Kalach N, Kori M, Madrazo A, Megraud F, Papadopoulou A, Rowland M, ESPGHAN, NASPGHAN (2017) Joint ESPGHAN/NASPGHAN guidelines for the Management of Helicobacter pylori in children and adolescents (update 2016). J Pediatr Gastroenterol Nutr 64:991–1003. https://doi.org/10.1097/MPG.0000000000001594
Brito HS, Braga JA, Loggetto SR, Machado R, Granato CF, Kawakami E (2015) Helicobacter pylori infection and immune thrombocytopenic purpura in children and adolescents: a randomized controlled trial. Platelets 26:336–341. https://doi.org/10.3109/09537104.2014.911836
Gonzalez-Lopez MA, Velazquez-Guadarrama N, Romero-Espejel ME, Olivares-Trejo Jde J (2013) Helicobacter pylori secretes the chaperonin GroEL (HSP60) which binds iron. FEBS Lett 587:1823–1828. https://doi.org/10.1016/j.febslet.2013.04.048
Malfertheiner P, Megraud F, O'Morain CA et al (2017) Management of Helicobacter pylori infection the Maastricht V/Florence Consensus Report. Gut 66:6–30. https://doi.org/10.1136/gutjnl-2016-312288
Kalach N, Bontems P, Raymond J (2017) Helicobacter pylori infection in children. Helicobacter 22:e12414. https://doi.org/10.1111/hel.12414
Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, Andersen LP, Goossens H, Glupczynski Y (2013) Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 62:34–42. https://doi.org/10.1136/gutjnl-2012-302254
Bell GD, Powell K, Burridge SM, Pallecaros A, Jones PH, Gant PW, Harrison G, Trowell JE (1992) Experience with ‘triple’ anti-Helicobacter pylori eradication therapy: side effects and the importance of testing the pre-treatment bacterial isolate for metronidazole resistance. Aliment Pharmacol Ther 6:427–435
Molina-Infante J, Lucendo AJ, Angueira T, Rodriguez-Tellez M, Perez-Aisa A, Balboa A, Barrio J, Martin-Noguerol E, Gomez-Rodriguez BJ, Botargues-Bote JM, Gomez-Camarero J, Huerta A, Modolell I, Ariño I, Herranz-Bachiller MT, Bermejo F, McNicholl AG, O'Morain C, Gisbert JP, the European Registry on H. pylori management (Hp-EuReg) (2015) Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. Alimet Pharmacol Ther 41:581–589. https://doi.org/10.1111/apt.13069
Joint FAO/WHO Working Group (2002) Report on drafting guidelines for the evaluation of probiotics in food. Available at: www.who.int/foodsafety/fs_management/en/probiotic_guidelines.pdf. Accessed 7 July 2018
Li S, Huang XL, Sui JZ, Chen SY, Xie YT, Deng Y, Wang J, Xie L, Li TJ, He Y, Peng QL, Qin X, Zeng ZY (2014) Meta-analysis of randomized controlled trials on the efficacy of probiotics in Helicobacter pylori eradication therapy in children. Eur J Pediatr 173:153–161. https://doi.org/10.1007/s00431-013-2220-3
Szajewska H (2014) Pooling data on different probiotics is not appropriate to assess the efficacy of probiotics. Eur J Pediatr 173:975. https://doi.org/10.1007/s00431-014-2340-4
Yang YJ, Chuang CC, Yang HB, Lu CC, Sheu BS (2012) Lactobacillus acidophilus ameliorates H. pylori-induced gastric inflammation by inactivating the Smad7 and NFkappaB pathways. BMC Microbiol 12:38. https://doi.org/10.1186/1471-2180-12-38
Myllyluoma E, Ahonen AM, Korpela R, Vapaatalo H, Kankuri E (2008) Effects of multispecies probiotic combination on Helicobacter pylori infection in vitro. Clin Vaccine Immunol 15:1472–1482. https://doi.org/10.1128/CVI.00080-08
Francavilla R, Lionetti E, Castellaneta SP, Magistà AM, Maurogiovanni G, Bucci N, de Canio A, Indrio F, Cavallo L, Ierardi E, Miniello VL (2008) Inhibition of Helicobacter pylori infection in humans by Lactobacillus reuteri ATCC 55730 and effect on eradication therapy: a pilot study. Helicobacter 13:127–134. https://doi.org/10.1111/j.1523-5378.2008.00593.x
Sgouras D, Maragkoudakis P, Petraki K, Martinez-Gonzalez B, Eriotou E, Michopoulos S, Kalantzopoulos G, Tsakalidou E, Mentis A (2004) In vitro and in vivo inhibition of Helicobacter pylori by Lactobacillus casei strain Shirota. Appl Environ Microbiol 70:518–526. https://doi.org/10.1128/AEM.70.1.518-526.2004
Mack DR, Ahrne S, Hyde L, Wei S, Hollingsworth MA (2003) Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro. Gut 52:827–833. https://doi.org/10.1136/gut.52.6.827
Borruel N, Casellas F, Antolin M, Llopis M, Carol M, Espiin E, Naval J, Guarner F, Malagelada JR (2003) Effects of nonpathogenic bacteria on cytokine secretion by human intestinal mucosa. Am J Gastroenterol 98:865–870. https://doi.org/10.1111/j.1572-0241.2003.07384.x
Mukai T, Asasaka T, Sato E, Mori K, Matsumoto M, Ohori H (2002) Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri. FEMS Immunol Med Microbiol 32:105–110
Lorca GL, Wadstrom T, Valdez GF, Ljungh A (2001) Lactobacillus acidophilus autolysins inhibit Helicobacter pylori in vitro. Curr Microbiol 42:39–44
Gotteland M, Cruchet S, Verbeke S (2001) Effect of Lactobacillus ingestion on the gastrointestinal mucosal barrier alterations induced by indometacin in humans. Aliment Pharmacol Ther 15:11–17
Marteau P, Minekus M, Havenaar R, Huisintveld JH (1997) Survival of lactic acid bacteria in a dynamic model of the stomach and small intestine: validation and the effects of bile. J Dairy Sci 80:1031–1037. https://doi.org/10.3168/jds.S0022-0302(97)76027-2
Bernet-Camard MF, Lievin V, Brassart D, Neeser JR, Servin AL, Hudault S (1997) The human Lactobacillus acidophilus strain LA1 secretes a nonbacteriocin antibacterial substance(s) active in vitro and in vivo. Appl Environ Microbiol 63:2747–2753
Klaenhammer TR (1993) Genetics of bacteriocins produced by lactic acid bacteria. FEMS Microbiol Rev 12:39–85
Bhatia SJ, Kochar N, Abraham P, Nair NG, Metha AP (1989) Lactobacillus acidophilus inhibits growth of Campylobacter pylori in vitro. J Clin Microbiol 27:2328–2330
Michetti P, Dorta G, Wiesel PH, Brassart D, Verdu E, Herranz M, Felley C, Porta N, Rouvet M, Blum AL, Corthésy-Theulaz I (1999) Effect of whey-based culture supernatant of Lactobacillus acidophilus (johnsonii) La1 on Helicobacter pylori infection in humans. Digestion 60:203–209. https://doi.org/10.1159/000007660
Higgins JPT, Green S (2011) Cochrane handbook for systematic reviews of interventions, version 5.1.0 (updated March 2011). The Cochrane Collaboration. Available at: www.handbook-5-1.cochrane.org/. Accessed 13 June 2018
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62:e1–34. https://doi.org/10.1016/j.jclinepi.2009.06.006
Schunemann H, Brozek J, Guyatt G et al (2013) GRADE handbook for grading quality of evidence and strength of recommendations (Updated October 2013). The GRADE Working Group Available at: www.guidelinedevelopment.org/handbook
Zhu XL, Liu Z, Wu ZQ, Li D, Jiang AP, Yu GX (2017) Clinical effects of different therapeutic regimens for Helicobacter pylori infection in children. Zhong Guo Dang Dai Er Ke Za Zhi 19:672–676. https://doi.org/10.7499/j.issn.1008-8830.2017.06.012
Weiner N, Shaoul R (2015) Impact of age, gender, and addition of probiotics on treatment success for Helicobacter pylori in children. Glob Pediatr Health 2:1–4. https://doi.org/10.1177/2333794X15607798
Tolone S, Pellino V, Vitaliti G, Lanzafame A, Tolone C (2012) Evaluation of Helicobacter Pylori eradication in pediatric patients by triple therapy plus lactoferrin and probiotics compared to triple therapy alone. Ital J Pediatr 38:63. https://doi.org/10.1186/1824-7288-38-63
Szajewska H, Albrecht P, Topczewska-Cabanek A (2009) Randomized, double-blind, placebo-controlled trial: effect of lactobacillus GG supplementation on Helicobacter pylori eradication rates and side effects during treatment in children. J Pediatr Gastroenterol Nutr 48:431–436. https://doi.org/10.1097/MPG.0b013e318182e716
Sykora J, Valeckova K, Amlerova J, Siala K, Dedek P, Watkins S, Varvarovska J, Stozicky F, Pazdiora P, Schwarz J (2005) Effects of a specially designed fermented milk product containing probiotic Lactobacillus casei DN-114 001 and the eradication of H. pylori in children: a prospective randomized double-blind study. J Clin Gastroenterol 39:692–698
Shahraki T, Shahraki M, Shahri ES, Mohammadi M (2017) No significant impact of Lactobacillus reuteri on eradication of Helicobacter pylori in children (double-blind randomized clinical trial). Iran Red Crescent Med J 19:e42101
Saneeyan H, Layegh S, Rahimi H (2011) Effectiveness of probiotic on treatment of Helicobacter pylori infection in children. J Isfahan Med Sch 29:882–889
Plewinska EM, Planeta-Malecka I, Bak-Romaniszyn L, Czkwianlanc E, Malecka-Panas E (2006) Probiotics in the treatment of Helicobacter pylori infection in children. Gastroenterol Pol 13(315–3):19
Ahmad K, Fatemeh F, Mehri N, Maryam S (2013) Probiotics for the treatment of pediatric Helicobacter pylori infection: a randomized double blind clinical trial. Iran J Pediatr 23:79–84
Graham DY, Fischbach L (2010) Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 59:1143–1153. https://doi.org/10.1136/gut.2009.192757
Zheng X, Lyu L, Mei Z (2013) Lactobacillus-containing probiotic supplementation increases Helicobacter pylori eradication rate: evidence from a meta-analysis. Rev Esp Enferm Dig 105:445–453. https://doi.org/10.4321/S1130-01082013000800002
Wang ZH, Gao QY, Fang JY (2013) Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy. J Clin Gastroenterol 47:25–32. https://doi.org/10.1097/MCG.0b013e318266f6cf
Sheu BS, Wu JJ, Lo CY, Wu HW, Chen JH, Lin YS, Lin MD (2002) Impact of supplement with Lactobacillus and Bifidobacterium containing yogurt on triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 16:1669–1675
Feng JR, Wang F, Qiu X, McFarland LV, Chen PF, Zhou R, Liu J, Zhao Q, Li J (2017) Efficacy and safety of probiotic-supplemented triple therapy for eradication of Helicobacter pylori in children: a systematic review and network meta-analysis. Eur J Clin Pharmacol 73:1199–1208. https://doi.org/10.1007/s00228-017-2291-6
Zhang MM, Qian W, Qin YY, He J, Zhou YH (2015) Probiotics in Helicobacter pylori eradication therapy: a systematic review and meta-analysis. World J Gastroenterol 21:4345–4357. https://doi.org/10.3748/wjg.v21.i14.4345
Lv Z, Wang B, Zhou X, Wang F, Xie Y, Zheng H, Lv N (2015) Efficacy and safety of probiotics as adjuvant agents for Helicobacter pylori infection: a meta-analysis. Exp Ther Med 9:707–716. https://doi.org/10.3892/etm.2015.2174
Lu M, Yu S, Deng J, Yan Q, Yang C, Xia G, Zhou X (2016) Efficacy of probiotic supplementation therapy for Helicobacter pylori eradication: a meta-analysis of randomized controlled trials. PLoS One 11:e0163743. https://doi.org/10.1371/journal.pone.0163743
Conflict of interest
The authors declare that they have no conflict of interest.
Not applicable for this manuscript.
Not applicable for this manuscript.
Communicated by Peter de Winter
Electronic supplementary material
About this article
Cite this article
Fang, H., Zhang, G., Cheng, J. et al. Efficacy of Lactobacillus-supplemented triple therapy for Helicobacter pylori infection in children: a meta-analysis of randomized controlled trials. Eur J Pediatr 178, 7–16 (2019). https://doi.org/10.1007/s00431-018-3282-z
- Triple therapy
- H. pylori